3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
10
Multiple Myeloma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Leukemia
5
Hodgkin Disease
5
Myelodysplastic Syndromes
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Mantle-Cell
4
Lymphoma
4
Hematologic Neoplasms
4
Anemia, Refractory, with Excess of Blasts
4
Recurrence
3
Primary Myelofibrosis
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Leukemia, Prolymphocytic
2
Leukemia, Plasma Cell
2
Burkitt Lymphoma
2
Thalassemia
1
Skin Neoplasms
1
Polycythemia Vera
1
Peritoneal Tumor
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myeloid Hematological Malignancies
1
Mesothelin-positive Advanced Malignant Solid Tumors
1
Interventions
fludarabine phosphate
1
fludarabine
1
Mesna
1
Cyclophosphamide
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Thalassemia
×
fludarabine
×
Clear all
NCT00578292
2020-05-01
THALLO
Baylor College of Medicine
Phase NA
Terminated
10 enrolled
15 charts